TCG Lifesciences, an India-based contract drug discovery and development company, today announced that it has entered into a partnership with Constella Group, a leading global provider of professional health services. As part of the non-exclusive relationship, TCG Lifesciences and Constella will jointly promote their contract services and identify and promote business opportunities across the two organizations.
Working with TCG Lifesciences’ clinical research and development arm (ClinInvent), Constella will expand its clinical trials services into India. Constella will promote ClinInvent’s clinical services to its clients interested in conducting clinical trials studies in India. In return, TCG Lifesciences will promote Constella’s services in Europe and the United States. Constella and TCG Lifesciences will work together to explore market opportunities in India for training, quality assurance, and regulatory affairs services.
“We are pleased to enter into this partnership with TCG Lifesciences,” said Don Holzworth, Constella’s Chairman and CEO. “India is attractive to pharmaceutical and biotechnology companies because of the rapid patient recruitment into clinical studies and the country’s highly skilled workforce. This partnership allows us to expand our services into new areas of the world.”
Commenting on the partnership Mr. Swapan Bhattacharya, Managing Director, TCG Lifesciences said, “We are confident that the alliance with Constella Group will allow us to further leverage our management team, significant experience in conducting clinical research & data management in India and access to clinicians across the country. Through this alliance the companies aim to jointly work on the drug development process through application of a translational research approach.
The partnership with TCG Lifesciences expands Constella’s reach into India. The company has a corporate office in New Delhi with more than 40 employees.